Roche has secured European Commission approval for Susvimo in neovascular age-related macular degeneration, giving the pharmaceutical group the European Union’s first continuous-delivery treatment designed to reduce the frequency of anti-VEGF therapy to as few as two scheduled refills a year. Susvimo continuously releases a customized formulation of ranibizumab through Roche’s refillable Contivue ocular implant, which is surgically placed during a one-time outpatient procedure and subsequently refilled approximately every 24 weeks.
The September 21 approval targets adults with wet age-related macular degeneration whose disease has stabilized after previously responding to an intravitreal VEGF inhibitor. European Medicines Agency documentation states that the implant maintained visual and anatomical outcomes comparable with ranibizumab injected into the eye every four weeks in the pivotal Phase 3 Archway study, while substantially reducing treatment frequency.
That distinction matters because the commercial battle in retinal disease is increasingly shifting away from whether anti-VEGF therapy can preserve vision and toward how long that benefit can be maintained between interventions. Roche already has one of the fastest-growing ophthalmology drugs in Vabysmo, while Bayer and Regeneron Pharmaceuticals have been extending the duration of Eylea 8 mg. Susvimo approaches the same problem differently by replacing repeated injections with a permanently implanted drug-delivery reservoir.
Why could two treatments a year change wet AMD care?
Neovascular age-related macular degeneration is driven by abnormal blood-vessel growth beneath the retina and can cause rapid central vision loss if inadequately treated. Roche estimates approximately 1.7 million people across the European Union are living with the disease, while roughly 20 million are affected globally.
Anti-VEGF medicines transformed the condition from one frequently associated with severe irreversible vision loss into a disease that can often be controlled. The trade-off is treatment burden. Many patients need repeated injections directly into the eye, sometimes over years, together with monitoring visits and retinal imaging.
That burden is particularly relevant because wet AMD primarily affects older adults. Patients may depend on relatives or caregivers for transport, while ophthalmology clinics must allocate appointment capacity, physicians, imaging equipment and injection rooms to a chronic population that repeatedly returns for treatment.
Roche said many patients cannot extend conventional anti-VEGF dosing beyond eight weeks and cited evidence that around 40% discontinue treatment within two years. Treatment discontinuation can have serious consequences because undertreated disease may allow fluid and abnormal blood vessels to return, potentially producing permanent loss of vision.
Susvimo therefore addresses a problem that is simultaneously clinical and operational. Instead of requiring patients to repeatedly return for drug injections, the implant continuously exposes the eye to ranibizumab between scheduled refill procedures.
How well did Susvimo work compared with monthly ranibizumab injections?
The European approval rests primarily on the Phase 3 Archway trial, supported by the Phase 2 Ladder study and the long-term Portal extension study. Archway compared the Susvimo delivery system with intravitreal ranibizumab administered every four weeks.
Roche reported that patients receiving Susvimo maintained vision outcomes equivalent to monthly ranibizumab injections. Longer-term Portal evidence showed that vision could be maintained for as long as seven years among followed patients, providing reassurance that continuous delivery can remain effective over a period relevant to chronic retinal disease.
The reduction in supplemental treatment is particularly important. Roche said approximately 95% of Susvimo-treated patients receiving two scheduled refills per year required no additional anti-VEGF treatment between those refills.
This is where the commercial argument becomes clearer. Susvimo does not necessarily need to produce superior vision improvement to conventional anti-VEGF injections if it can provide comparable disease control with substantially fewer treatment procedures.
For an elderly patient facing years of ophthalmology appointments, six-month refill intervals can represent a meaningful quality-of-life improvement. For health systems, reducing repetitive injections could free clinical capacity for other patients.
Why is Susvimo not simply a more convenient version of an eye injection?
The convenience advantage comes with an important trade-off: the implant requires surgery.
Contivue is inserted into the eye during a one-time outpatient procedure, after which the device remains in place and is refilled rather than replaced at each treatment interval. The European Medicines Agency specifies that implantation should be performed by an ophthalmologist experienced in vitreoretinal surgery and trained in the procedure.
That means Susvimo changes rather than eliminates treatment complexity. Conventional anti-VEGF therapy involves repeated injections but no permanent implanted device. Susvimo reduces recurring treatment frequency but introduces an initial surgical procedure and implant-specific risks.
United States prescribing information provides an important indication of those risks. Susvimo carries a boxed warning for endophthalmitis, a serious infection inside the eye, and the implant has been associated with an endophthalmitis rate up to three times higher than monthly intravitreal ranibizumab injections. Other identified risks include retinal detachment, implant movement, vitreous hemorrhage, conjunctival erosion or retraction and other implant-related complications.
Those risks do not negate the European approval, which reflects regulators’ conclusion that benefits outweigh risks in the indicated population when the treatment is used appropriately. They do mean that Susvimo will probably be most attractive where physicians and patients value substantial reductions in repeated injections enough to accept a surgical implant and its associated monitoring requirements.
How does Susvimo compete with longer-lasting injections such as Eylea 8 mg?
The retinal market is increasingly competing on durability.
Regeneron Pharmaceuticals’ Eylea HD, marketed as Eylea 8 mg outside the United States through Bayer, has progressively extended treatment intervals. In the United States, wet AMD patients who respond successfully can now be considered for intervals as long as 20 weeks after the first year of treatment.
This means Susvimo is not competing against monthly injections alone. Modern anti-VEGF therapies can already allow some patients to go several months between treatments.
The difference is the delivery model. Eylea 8 mg remains an injection given when treatment is due. Susvimo continuously releases medicine from an implanted reservoir, creating a scheduled six-month refill model rather than progressively extending individual injections.
Roche also competes with itself through Vabysmo, its bispecific retinal medicine targeting VEGF-A and Ang-2. Vabysmo has become one of Roche’s largest growth products and generated CHF2.06 billion in first-half 2026 sales, increasing 8% at constant exchange rates.
That apparent internal competition is strategically useful. Roche can offer physicians different approaches within the same ophthalmology franchise: Vabysmo for patients who prefer injectable treatment with extended intervals and Susvimo for suitable patients who prioritize continuous delivery through an implanted system.
Why could the Contivue implant become more valuable than Susvimo alone?
Roche has made clear that Contivue is intended to become more than a single-drug delivery device. The company is evaluating additional molecules that could potentially use the same port-delivery platform with the objective of increasing efficacy, durability or the range of retinal diseases treated.
That changes the strategic interpretation of the approval.
If Contivue remains tied only to ranibizumab, its value depends primarily on how many wet AMD patients choose Susvimo over modern injectable competitors. If Roche successfully places newer medicines into the implant, Contivue could become a reusable drug-delivery platform supporting multiple generations of retinal therapy.
This type of platform strategy is particularly attractive in medical technology because the first installation creates a durable connection with the patient and treating physician. Once an implant is surgically placed, switching treatment systems is potentially more involved than changing from one conventional injection to another.
The installed base could therefore become strategically valuable over time, especially if future drugs provide longer durability or stronger retinal drying.
How important is ophthalmology to Roche’s current growth story?
Roche reported first-half 2026 pharmaceutical sales of CHF23.63 billion, increasing 6% at constant exchange rates. Vabysmo was one of the group’s five largest pharmaceutical growth contributors alongside Xolair, Hemlibra, Ocrevus and Phesgo. Those five medicines generated combined first-half sales of CHF11 billion.
Vabysmo’s CHF2.06 billion first-half revenue shows that Roche has already built a meaningful commercial ophthalmology franchise before Susvimo’s European launch. International Vabysmo sales increased particularly rapidly, rising 65% at constant exchange rates, while Japanese sales climbed 26%.
Susvimo provides a different kind of growth opportunity because it potentially expands Roche’s share of treatment rather than merely adding another injectable molecule. Physicians who prefer continuous delivery could remain within Roche’s ecosystem even where they might otherwise choose a longer-lasting competing anti-VEGF medicine.
Europe is also strategically meaningful. Roche generated CHF4.52 billion of pharmaceutical sales in Europe during the first half, although growth was only 1% at constant exchange rates. A differentiated product capable of establishing a new retinal treatment model could therefore contribute incremental growth in a region where overall pharmaceutical expansion has been comparatively modest.
What does the Susvimo approval mean for Roche investor sentiment?
Roche participation shares closed at CHF364.80 on September 21, gaining 2.24% for the session, while Roche bearer shares closed at CHF373.20, up 2.30%. The participation certificates remained close to their 52-week high of CHF375.80.
The strong session should not be attributed entirely to Susvimo. Roche has had several pipeline and business developments circulating simultaneously, and a diversified group of its scale is rarely revalued materially because of one ophthalmology approval.
The wider sentiment backdrop has nevertheless strengthened. Roche reported 6% constant-currency group sales growth in the first half and 10% growth in core operating profit at constant exchange rates, while several analysts have recently highlighted its pipeline and pharmaceutical momentum.
Susvimo therefore adds to an existing growth narrative rather than creating one on its own.
What should determine whether Susvimo becomes commercially important in Europe?
The first test is physician adoption. Ophthalmologists need to decide which patients justify a surgical implant rather than continued injections, particularly as injectable therapies themselves become more durable.
The second is reimbursement. A port-delivery system involves upfront procedural and device costs but could reduce repeated treatment visits over subsequent years. European health systems will need to judge that entire economic pathway rather than comparing only medicine acquisition prices.
Safety will remain the third decisive factor. Implant-related complications can be serious, and success will depend partly on surgeon training, patient selection and early recognition of conjunctival or infectious problems.
Finally, Roche must demonstrate whether continuous delivery can produce meaningful real-world persistence. Clinical trials show that around 95% of patients could avoid supplemental injections between scheduled refills, but routine practice will determine whether that advantage survives across broader and older patient populations.
The European approval nevertheless represents an important change in retinal medicine. The anti-VEGF market has spent years trying to stretch the interval between injections. Roche is now offering another answer: instead of repeatedly extending injections, leave a refillable reservoir inside the eye and deliver medicine continuously.
That turns the wet AMD competition from a contest over molecules into a contest over treatment systems. If patients and physicians accept the surgical trade-off, Susvimo could make twice-yearly refilling a credible alternative to the repeated injections that have defined anti-VEGF treatment for more than a decade.
